Sweta Dalal

Ms. Sweta Dalal

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ANAnroop B Nair
Anroop B Nair
Sunil KumarSunil Kumar
Sunil Kumar
PDPooja Dalal
Pooja Dalal
CNChahat Nagpal
Chahat Nagpal
SDSweta Dalal
Sweta Dalal
SJShery Jacob
Shery Jacob
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.

11 March 2022 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
SMSidharth Mehta
Sidharth Mehta
VKVarsha Kadian
Varsha Kadian
SDSweta Dalal
Sweta Dalal
PDPooja Dalal
Pooja Dalal
Sunil KumarSunil Kumar
Sunil Kumar
RRRekha Rao
Rekha Rao
Bergenin (BER), a key constituent of Bergenia crassifolia (Saxifragaceae), has gained extensive attention, owing to its array of pharmacological actions, including anti-infective, anti-cancer, anti-diabetic, neuroprotective, hepatoprotective, anti-urolithiatic, anti-hyperuricemic, and anti-bradykinin properties. Despite ever-intensifying support for its therapeutic features, the poor solubility, lower oral bioavailability, shorter half-life, and more intestinal pH degradation (pH 6.8 or above) of BER have puzzled researchers. To circumvent these pharmaceutical challenges, and to improve its therapeutic efficacy, newer approaches have been adopted by research scientists. Thus, a discussion of the existing literature may provide complete information about the advances in delivery strategies for enhancing its utility. This paper summarizes up-to-date works on the design and development of novel delivery carriers of this bioactive compound, such as phospholipid complexes, extended-release core tablets, prodrugs, herbal gels, polyherbal ointments, nanoparticles, and poly (lactic acid) polymers, with the objective of harnessing its full potential. This review also provides a deep insight into its bioactivities, along with mechanisms. Additionally, the physicochemical attributes, chemistry, and pharmacokinetics of BER are discussed herein. Hence, the comprehensive information documented in this review may introduce new avenues for research advancements of BER.

13 November 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
VKVarsha Kadian
Varsha Kadian
BJBabu Lal Jangir
Babu Lal Jangir
PDPooja Dalal
Pooja Dalal
Sunil KumarSunil Kumar
Sunil Kumar
ANAnroop B Nair
Anroop B Nair
RRRekha Rao
Rekha Rao